Skip to main content
. Author manuscript; available in PMC: 2021 Jul 13.
Published in final edited form as: Cancer Cell. 2020 May 30;38(1):60–78.e12. doi: 10.1016/j.ccell.2020.05.001

Figure 3. Human SCLC subtypes correspond with MYC-driven evolution.

Figure 3.

(A) Log2-fold change of indicated NE (relative to the last time point) and non-NE pathway genes (relative to the first time point) from bulk RNA-seq of primary RPM tumor cells at specific days in culture. Dashed lines in Notch signaling panel indicate genes predicted to be Notch-inhibitory.

(B) GSEA of 50-gene NE and non-NE gene signature from (Zhang et al., 2018) applied to early (day 3-7) vs late (day 14-21) time points of RPM transition.

(C) Log2 expression of SCLC-subtype defining transcription factor genes at indicated time points from bulk RNA-seq data of RPM transition.

(D) GSEA for human SCLC-ASCL1 (SCLC-A), SCLC-NEUROD1 (SCLC-N) and SCLC-YAP1 (SCLC-Y) gene signatures applied to bulk RNA-seq data grouped in day increments.

See also Figure S3 and Table S1.